The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Neurocrine Biosciences, Inc. shares valued at $37,346 were sold by Delaet Ingrid on Apr 01 ’24. At $137.30 per share, Delaet Ingrid sold 272 shares. The insider’s holdings dropped to 7,507 shares worth approximately $1.02 million following the completion of this transaction.
Also, Delaet Ingrid sold 5,000 shares, netting a total of over 725,320 in proceeds. Following the sale of shares at $145.06 each, the insider now holds 7,507 shares.
Before that, BENEVICH ERIC had sold 75,000 shares from its account. In a trade valued at $10,453,417, the Chief Commercial Officer traded Neurocrine Biosciences, Inc. shares for $139.38 each. Upon closing the transaction, the insider’s holdings decreased to 75,000 shares, worth approximately $5.54 million.
Analysts at Deutsche Bank started covering the stock with ‘”a Buy”‘ outlook in a report released in mid December. Earlier on August 21, 2023, Mizuho resumed its rating. Their recommendation was “a Neutral” for NBIX stock.
Analyzing NBIX Stock Performance
During the last five days, there has been a drop of approximately -1.22%. Over the course of the year, Neurocrine Biosciences, Inc. shares have jumped approximately 3.16%. Shares of the company reached a 52-week high of $148.37 on 03/21/24 and a 52-week low of $128.00 on 02/07/24. A 50-day SMA is recorded $137.03, while a 200-day SMA reached $119.20. Nevertheless, trading volume fell to 0.81 million shares from 0.6 million shares the previous day.
Support And Resistance Levels for Neurocrine Biosciences, Inc. (NBIX)
According to the 24-hour chart, there is a support level at 134.58, which, if violated, would cause prices to drop to 133.24. In the upper region, resistance lies at 137.97. The next price resistance is at 140.02. RSI (Relative Strength Index) is 44.31 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -1.22, which suggests the price will decrease in the coming days. Percent R is at 79.12%, indicating bearish price movement. Stochastics %K at holding indicates that the stock is to be held.
Is Neurocrine Biosciences, Inc. subject to short interest?
Stocks of Neurocrine Biosciences, Inc. saw a sharp rise in short interest on Mar 28, 2024 jumping by 0.25 million shares to 2.43 million. Data from Yahoo Finance shows that the short interest on Feb 29, 2024 was 2.18 million shares. A jump of 10.29% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 2.38 of the overall float, the days-to-cover ratio (short ratio) jumped to 2.38.
